Director GRYSKA DAVID W bought 2,500 shares at $7.17; stock now at $7.11, up 19.6% over 90 days from unprofitable company.
GRYSKA DAVID W purchased 2,500 shares on 2024-12-05 at $7.17, increasing his holdings from 17.4K to 19.9K shares—a 14.4% increase in his position. The company is unprofitable with net income of $-13.7M, and the stock trades 39.5% below its 52-week high of $11.75. His prior buy at this ticker on 2024-08-23 generated a 90-day return of +18.6%, a well-timed entry. This current purchase comes after the stock has rallied 19.6% over the last 90 days and 15.6% over the last 30 days, suggesting he is buying into positive momentum rather than a depressed or recovery scenario. The timing and magnitude of this open-market purchase merit monitoring given the company's unprofitable status and the stock's extended position off its recent lows.
Director David W Gryska bought 3,500 shares of MNMD at $5.98 on 2024-08-23; stock down 34.9% in 30 days and -47.9% from 52-week high.
Director David W Gryska purchased 3,500 shares at $5.98, increasing his holdings by 25.3% to 17,351 shares post-transaction. The purchase occurs during a period of significant price deterioration: the stock has declined 34.9% over the past 30 days and 47.9% from its 52-week high of $11.75. Mind Medicine is unprofitable with net income of $-5.9M in its most recent full fiscal year, a fundamental weakness that undercuts the significance of the open-market buy signal. The combination of sustained downward price momentum, unprofitable operations, and a director's mid-downturn accumulation suggests monitoring rather than conviction, as the broader context lacks earnings stability to support a bullish interpretation of the insider purchase.
